5ht2c receptor modulators

Abstract

The present invention relates to novel compounds of Formula (I): which act as 5HT 2C receptor modulators. These compounds are useful in pharmaceutical compositions whose use includes the treatment of obesity.

1 - 12 . (canceled) 
     
     
         13 . A method for weight loss in an individual in need thereof, comprising administering an oral dose of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt thereof to the individual. 
     
     
         14 . The method according to  claim 13 , wherein the dose is administered in the form of a tablet. 
     
     
         15 . The method according to  claim 13 , wherein the method further comprises placing the individual on a diet. 
     
     
         16 . The method according to  claim 13 , wherein the method further comprises increasing the physical activity of the individual. 
     
     
         17 . The method according to  claim 13 , wherein the individual has an initial body mass index (BMI) of 30 kg/m 2  or greater. 
     
     
         18 . The method according to  claim 13 , wherein the individual has at least one weight-related condition selected from: hypertension and type 2 diabetes. 
     
     
         19 . A method for weight loss in an individual in need thereof, comprising administering an oral dose of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt thereof to the individual, wherein the (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or pharmaceutically acceptable salt thereof is administered in conjunction with a diet and increased physical activity. 
     
     
         20 . The method according to  claim 19 , wherein the dose is administered in the form of a tablet. 
     
     
         21 . The method according to  claim 19 , wherein the individual has an initial body mass index (BMI) of 30 kg/m 2  or greater. 
     
     
         22 . The method according to  claim 19 , wherein the individual has at least one weight-related condition selected from: hypertension and type 2 diabetes. 
     
     
         23 . A method for treating obesity in an individual in need thereof, comprising administering an oral dose of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt thereof to the individual. 
     
     
         24 . The method according to  claim 23 , wherein the dose is administered in the form of a tablet. 
     
     
         25 . The method according to  claim 23 , wherein the method further comprises placing the individual on a diet. 
     
     
         26 . The method according to  claim 23 , wherein the method further comprises increasing the physical activity of the individual. 
     
     
         27 . The method according to  claim 23 , wherein the individual has at least one weight-related condition selected from: hypertension and type 2 diabetes. 
     
     
         28 . A method for treating obesity in an individual in need thereof, comprising administering an oral dose of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt thereof, wherein the (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or pharmaceutically acceptable salt thereof is administered in conjunction with a diet and increased physical activity. 
     
     
         29 . The method according to  claim 28 , wherein the dose is administered in the form of a tablet. 
     
     
         30 . The method according to  claim 28 , wherein the weight-related condition is selected from: hypertension and type 2 diabetes.